Experiencia con el uso de plasma rico en plaquetas autólogo en el tratamiento de las úlceras del pie diabético / Use of platelet rich plasma in the treatment of diabetic foot ulcers. Report of the experience / Experiência com o uso de plasma autólogo rico em plaquetas no tratamento de úlceras do pé diabético

Resumen: Las úlceras de pie diabético (UPD) generan un alto costo para el paciente y el sistema de salud. Una deficiente vascularización, la inhibición de la generación de factores de crecimiento y la migración celular, entre otros factores, influyen en su cronicidad. Los factores de crecimiento derivados de las plaquetas (PDGF) estimulan la quimiotaxis, la neovascularización y la regeneración tisular. Objetivo: evaluar la efectividad de una formulación de plasma rico en plaquetas autólogo (PRP) como una modalidad complementaria para el tratamiento de UPD, valorando su seguridad y efectos adversos. Materiales: estudio observacional. Se aplicó PRP a seis pacientes con UPD crónicas, Wagner II, III, con una media en el retraso de la cicatrización de 94 semanas. Se administró mediante punción y como gel sobre la lesión una vez por semana hasta el cierre de la úlcera o durante12 semanas. Las UPD se analizaron con respecto al área y su progresión mediante Mobile Wound Analyzer (MOWA), software de análisis de imágenes de úlceras. El porcentaje de reducción del área se calculó entre la medición inicial y la semana 12. Como criterio de mejoría se eligió una reducción >70% de la lesión. Resultados: predominó el sexo masculino con una media de edad de 53 años ± 7,3. Luego de 12 semanas de tratamiento, se reportó una reducción media del tamaño de la úlcera de 78%, con dos cicatrizaciones completas y dos en 99%. Un paciente recibió una amputación luego de presentar infección no controlada. Conclusión: la aplicación del PRP mejoró la regeneración de tejidos, acortando la duración de la úlcera, promoviendo su curación sin efectos adversos, al tiempo que eliminó la necesidad de procedimientos de manejo en una úlcera crónica.

Summary: Diabetic foot ulcers imply high expenditure for both patients and the health system. Vascular impairment, growth factor inhibition and cell migration, among other factors, affect the chronicity of the condition. Platelet-derived growth factors (PDGFs) stimulate chemotaxis, neovascularization and tissue regeneration. Objective: to evaluate effectiveness of a formulation of autologous platelet-rich plasma to complement the treatment of diabetic foot ulcer, assessing safety and adverse effects. Material: observational study. Platelet rich plasma was applied to six patients with chronic diabetic foot ulcer Wagner II, III, with an average delayed healing of 94 weeks. PRP gel was administered by puncture technique on the lesion, once a week until the ulcer healed or for 12 weeks. Diabetic foot ulcers were analysed in regards to surface area and progression through the Mobile Wound Analyzer (MOWA) software to analyse ulcer images. The area reduction percentage was calculated comparing the initial measurement and that of week 12. The improvement criteria was defined in a reduction that is >70% of the lesion. Results: men prevailed with an average age of 53 years ± 7.3. After 12 weeks of treatment an average reduction of 78% of the size of the ulcer was reported, two complete healings and two 99% healed. One patient required amputation because of uncontrolled infection. Conclusion: the application of PRP improved tissue regeneration and shortened the duration of the ulcer, promoting healing with no adverse effects, and it likewise eliminated the need for procedures to handle chronic ulcers.

Resumo: As úlceras do pé diabético (UPD) geram alto custo para o paciente e para o sistema de saúde. A vascularização deficiente, a inibição da geração de fatores de crescimento e migração celular, entre outros fatores, influenciam sua cronicidade. Os fatores de crescimento derivados de plaquetas (PDGF) estimulam a quimiotaxia, a neovascularização e a regeneração de tecidos. Objetivo: avaliar a eficácia de uma formulação autóloga de plasma rico em plaquetas (PRP) como modalidade complementar para o tratamento da UPD, avaliando sua segurança e efeitos adversos. Materiais: estudo observacional. O PRP foi aplicado a 6 pacientes com UPD crônica, Wagner II, III, com um atraso médio na cicatrização de 94 semanas. Foi administrado por punção e como gel sobre a lesão uma vez por semana até o fechamento da úlcera ou por 12 semanas. As UPD foram analisadas em relação à área e sua progressão, utilizando o software de análise de imagem de úlcera Mobile Wound Analyzer (MOWA). A redução percentual da área foi calculada entre a medição inicial e a semana 12. Como critério de melhora, optou-se pela redução > 70% da lesão. Resultados: predominou o sexo masculino com média de idade de 53 ± 7,3 anos. Após 12 semanas de tratamento, foi relatada uma redução média no tamanho da úlcera de 78%, sendo 2 com cicatrização completa e 2 em 99%. Um paciente foi amputado após desenvolver infecção descontrolada. Conclusão: a aplicação do PRP melhorou a regeneração tecidual, encurtando o tempo de duração da úlcera, promovendo sua cicatrização sem efeitos adversos, ao mesmo tempo que eliminava a necessidade de procedimentos de manejo na úlcera crônica.

Stimul W® y Heberprot-P® unidos en el tratamiento de la úlcera del pie diabético / Stimul W® and Heberprot-P® combined for treating diabetic foot ulcer

Introducción: Las úlceras del pie diabético resultan las complicaciones más frecuentes en las personas con diabetes. Se conocen diferentes formas de tratamiento para esta enfermedad, con más o menos efectividad, pero no resuelven el problema en la totalidad de los casos. El estimulador eléctrico Stimul W® y el medicamento Heberprot-P® se han empleado, de manera independiente y con resultados satisfactorios, como alternativas para el tratamiento de estas lesiones. Comprobar si la acción combinada de ambos procedimientos permite alcanzar mejores resultados, permitiría contribuir a resolver un problema de alta prevalencia mundial. Objetivo: Exponer el resultado de la aplicación de la combinación del estimulador Stimul W® y el medicamento Heberprot-P® en el tratamiento de un paciente con úlcera del pie diabético. Presentación del caso: Paciente masculino de 69 años de edad, con diabetes mellitus de tipo 2, que presentaba una úlcera del pie diabético en la parte externa del pie derecho, con abundante tejido necrótico en forma de fístula en la base de los dos dedos restantes y falta de granulación. Los tratamientos anteriores no dieron el resultado esperado. Se decidió, como terapia de curación, aplicar durante 12 sesiones la combinación del estimulador Stimul W® y el medicamento Heberprot-P®. Conclusiones: Se logró la cicatrización de la lesión, al obtener un 100 por ciento de tejido de granulación y la disminución significativa de sus dimensiones, lo que mostró que la terapia aplicada constituye una alternativa para el tratamiento de este tipo de úlcera(AU)

Introduction: Diabetic foot ulcers are the most frequent complications in people with diabetes. Different forms of treatment for this disease are known, with more or less effectiveness; but they do not solve the problem in all cases. The electrical stimulator Stimul W® and the drug Heberprot-P® have been used independently, and with satisfactory outcomes, as alternatives for the treatment of these lesions. Checking whether the combined action of both procedures allows to achieve better outcomes would contribute to solve a problem of high worldwide prevalence. Objective: To present the outcomes of applying the combination of the stimulator Stimul W® and the drug Heberprot-P® for treating a patient with diabetic foot ulcer. Case presentation: A 69-year-old male patient, with type 2 diabetes mellitus, who presented with a diabetic foot ulcer on the outside of the right foot, with abundant necrotic tissue in the form of a fistula at the base of the two remaining toes and lack of granulation. The previous treatments did not permit the expected outcomes. It was decided, as a healing therapy, to apply the combination of the stimulator Stimul W® and the drug Heberprot-P® for twelve sessions. Conclusions: Healing of the lesion was achieved by obtaining 100 percent granulation tissue and a significant reduction in its dimensions, which showed that the applied therapy constitutes an alternative for the treatment of this type of ulcer(AU)

Recidiva de úlcera del pie en pacientes diabéticos tratados con Heberprot-P® / Foot ulcer recurrence in diabetic patients who received heberprot-p® treatment

Introducción: El Heberprot-P® es un medicamento novedoso y único en su tipo, prescrito para la terapia de la úlcera del pie diabético. Objetivo: Evaluar la frecuencia y las características de la recidiva de úlcera del pie en pacientes diabéticos tratados con Heberprot-P®. Métodos: Se realizó una investigación descriptiva-retrospectiva. La población estuvo constituida por 16 pacientes con recidiva de úlcera de pie diabético de los 841 tratados con Heberprot-P® en policlínicos y hospitales de la provincia de Matanzas desde enero hasta diciembre de 2018. Las variables revisadas fueron llevadas a una base de datos, y los resultados obtenidos se tabularon y se expresaron en frecuencias absolutas y relativas. Se respetaron las consideraciones éticas requeridas para este estudio. Resultados: El grupo de edades 61-75 años y los diabéticos de tipo 2 fueron los más afectados, y no existieron diferencias entre ambos sexos. El pie diabético neuropático con una severidad Wagner 2 se manifestó con mayor frecuencia. Asimismo, a partir de la primera lesión y la recidiva se observó un gran número de pacientes con la enfermedad entre las 13 y 16 semanas, y al 56,2 por ciento de estos se les administró, durante la primera lesión, de 6 a 12 dosis de Heberprot-P®. El cierre total de la lesión en el desenlace fue lo más encontrado en la población de estudio, y el 1,9 por ciento de los pacientes tratados presentó una recidiva de esta. Conclusiones: Quedaron expuestas la frecuencia y las características de la recidiva de la úlcera del pie en los pacientes diabéticos tratados con Heberprot-P®(AU)

Introduction: Heberprot-P® is a novel medicine, unique among its kind, prescribed for diabetic foot ulcer therapy. Objective: To evaluate frequency and characteristics of foot ulcer recurrence among diabetic patients treated with Heberprot-P®. Methods: A descriptive-retrospective research was carried out. The study population consisted of 16 patients with diabetic foot ulcer recurrence from among the 841 treated with Heberprot-P® in polyclinics and hospitals in Matanzas Province from January to December 2018. The variables reviewed were taken to a database, and the results obtained were represented in charts and expressed in absolute and relative frequencies. The ethical considerations required for this study were respected. Results: The age group 61-75 years and type 2 diabetic patients were the most affected. There were no differences between both sexes. Neuropathic diabetic foot with Wagner 2 severity appeared more frequently. Likewise, after the first injury and recurrence, a large number of patients with the disease were observed at 13-16 weeks, 56.2 percent of whom, were administered, during the first injury, 6-12 doses of Heberprot-P®. The total closure of the lesion was the most found outcome in the study population, and 1.9 percent of the treated patients presented recurrence of this. Conclusions: The frequency and characteristics of foot ulcer recurrence in diabetic patients treated with Heberprot-P® were exposed(AU)

Tratamento da úlcera plantar devido à hanseníase / Treatment of leprosy-induced plantar ulcers

Introdução: A úlcera plantar por hanseníase é uma lesão no pé resultante da falta de sensibilidade plantar. O objetivo é descrever o tratamento realizado em portadores de úlceras plantares por hanseníase. Métodos: Estudo de prontuários de portadores de úlcera plantar atendidos no Hospital Sarah em Brasília, de 2006 a 2016, quanto ao sexo, idade, etiologia, localização e tratamento. Resultados: Foram atendidos 27 pacientes, 17(62,96%) homens e 10 (37,04%) mulheres, procedentes de Goiás e DF, na faixa etária de 41 a 60 anos (40,74%). Todos necessitaram de um ou mais procedimentos cirúrgicos. Conclusão: Observou-se maior frequência no sexo masculino, grau avançado, localizadas no primeiro artelho. Todos necessitaram de procedimentos cirúrgicos e não cirúrgicos, evoluindo com cicatrização completa da ferida, amputação transtibial em um caso e de artelhos em sete casos, e 90% dos casos apresentaram recorrência da úlcera após um ano.

Introduction: Leprosy-induced plantar ulcers result from a lack of plantar sensitivity. Objective: This study aimed to describe the treatment provided to patients with leprosy-induced plantar ulcers. Methods: We retrospectively reviewed the medical records of patients with plantar ulcers treated at Sarah Hospital in Brasilia from 2006 to 2016 and collected information about sex, age, etiology, location, and treatment. Results: A total of 27 patients (17 [62.96%] men, 10 [37.04%] women; 40.74% were aged 41­60 years) were treated from Goiás and the Federal District. All required ≥1 surgical procedure. Conclusion: A higher frequency of advanced grade was observed in men, primarily on the first toe. All needed surgical and non-surgical procedures and achieved complete wound healing. Transtibial amputation was required in 1 case and toe amputation in 7 cases; 90% patients developed ulcer recurrence after 1 year.

Atenção integral ao portador de pé diabético / Comprehensive care to patients with diabetic foot

São apresentadas, nessa separata, as principais orientações sobre a atenção às complicações do pé diabético. A neuropatia, com suas diversas apresentações que acometem os membros inferiores dos diabéticos, as lesões da doença arterial obstrutiva periférica (DAOP), as múltiplas apresentações da infecção do pé diabético, e, principalmente, os cuidados preventivos que possam impedir o estabelecimento ou a evolução dessas complicações são tratados de forma sistemática e simplificada, visando a atenção integral desses doentes. Especial cuidado é dado às orientações diferenciadas para os diversos níveis de atenção nos serviços públicos de saúde, porta de entrada virtual de 80% dos infelizes portadores dessa complicação. São aqui apresentados modelos de atenção e sugeridos protocolos que podem contribuir para a efetiva redução do número de amputações, internações e óbitos de diabéticos com complicações nos membros inferiores.

Pé diabético: relato de caso e protocolo assistencial do serviço de endocrinologia do Hospital de Clínicas de Porto Alegre / Diabetic foot: a case report and endocrinology unit of Hospital de Clínicas de Porto Alegre assistance protocol

A infecção do pé é uma importante causa de morbidade em pacientes com diabetes melito, sendo responsável pela maioria dos casos de amputação não traumática de membros inferiores. A ulceração, secundária principalmente à neuropatia diabética, deformidade e trauma, é o principal fator de risco para infecção. Prevenção e identificação precoce dessas alterações, com tratamento apropriado, constituem ferramentas essenciais para diminuir a morbidade relacionada. Neste artigo, relatamos o caso de um paciente com diabetes melito tipo 2 e infecção de pé diabético, com predominância de componente neuropático, e descrevemos o protocolo assistencial recomendado pelo Serviço de Endocrinologia do Hospital de Clínicas de Porto Alegre (HCPA).

Infection of the foot is a major cause of morbity in patients with diabetes mellitus and is responsible for most cases of nontraumatic amputation of lower limbs. The ulceration, mainly secondary to diabetic neuropathy, deformity and trauma, is the main risk factor for infection. Prevention and early identification of these changes, along with its appropriate treatment are essential tasks to reduce morbidity related. We report a case of a patient with type 2 diabetes mellitus and infection of diabetic foot, mainly presenting neuropathy, and describe the protocol of care recommended by the Endocrinology Unit of the Hospital de Clínicas de Porto Alegre (HCPA).

[Efficacy of oral angipars in chronic diabetes foot ulcer: a double blind placebo controlled study]

Diabetes mellitus is the most common human metabolic disease and chronic non healing diabetic foot ulcers are a critical complication for these patients. ANGIPARS is a new herbal extract which has been introduced to accelerate healing of these ulcers. The purpose of this study was to investigate the efficacy and safety of oral ANGIPARS in patients with chronic diabetic foot ulcers and also its effect on inflammatory blood markers. In a double-blind placebo-controlled trial, 40 patients with diabetic foot ulcers of at least 4 weeks duration, were randomized to receive either oral ANGIPARS, or placebo twice a day, until the ulcer was completely healed or for a maximum of 6 weeks and followed up to 12 weeks. Standard foot ulcer care was given to all patients. The healing process was assessed with measuring ulcer surface area and time needed to achieve complete wound healing. Drug safety was assessed by monitoring adverse events, using clinical and laboratory evaluations. In both groups, wound surface area decreased significantly [p<0.0005]. Mean improvement ratio was 95.8% in the ANGIPARS group and 79.2% in the placebo group, although mean percent of wound area reduction in the former group was higher than in the placebo group at weekly assessments, this difference was not statistically significant [p=0.25] except for at the 4[th] week. [84/2% vs. 56%, p=0.013] Ultimately, complete wound healing was achieved in 90% and 70% of ANGIPARS group and placebo group, respectively, after 12 weeks. Time to achieve complete wound healing, also, was not different significantly in either groups. [6.2 vs 7.4 weeks, p=0.3] Significant reduction in ESR was sent in the ANGIPARS group. [p=0.04] There was no significant changes in laboratory parameters. Two complications most likely attributable to ANGIPARS reported were worsening of proliferative diabetic retinopathy in one patient and acute renal failure and acute hepatitis in another patient with diabetic nephropathy. Although ANGIPARS enhanced wound healing at least within weeks 2 to 4 of treatment, we did not observe a significant effect in the outcome. Therefore, standard foot ulcer care seems to be the cornerstone of diabetic foot ulcer management and ANGIPARS should probably be reserved for treatment of the non-healing or difficult-to-heal ulcers that do not respond to standard treatments. Further studies are required to assess the efficacy of this new herbal extract

Treatment of diabetic leg ulcer by local application of honey and olive oil mixture

Wound care is one of the main concerns of patients with diabetes This case involved a 55-year-old man with uncontrolled type 2 diabetes mellitus developed medial leg ulcer [2cm x 2cm] due to accident, for which he received currently recommended therapy, including antibiotic and betadin dressing. After 2 months of care the ulcer did not improved. Patient referred to diabetic clinic with 2x2x2 cm medial leg ulcer. After rule out of osteomylitis and discontinuation of antibiotic and betadin dressing, once-daily thick applications of honey and olive oil mixture were started. Granulation tissue appeared within 5 days and in one month the ulcer resolved Two weeks later, the ulcer has not been recurred

Hacia una prevención primaria y secundaria del pie diabético. Semiología del pie / Toward a primary and secondary prevention for amputations of the feet in diabetic patientss

Chronic complications of diabetes are the most important cause of morbidity of the disease, which constitutes a major public health problem. Patientes with diabetes are more prone to develop premature atherosclerotic disease in the lower extremities, which leads to frequent hospitalizations for common lower extremity amputations... This report offers guidelines for the management of a foot, which is threatened, with loss of the blood supply due to impairment of the circulation of the lower limbs, in diabetic patients.

Problemas en los pies de los pacientes con diabetes (segunda entrega): evaluación y manejo de las infecciones / Feet problems in diabetic patients (second part): evaluation and management of infections

La afección del pié en los pacientes con diabetes constituye por su importancia una entidad en si misma. En el espectro de su afectación encontraremos desde simples cambios en la sensibilidad y el trofismo de la piel, hasta úlceras de diferente magnitud, lesiones necróticas y osteomielitis, que pueden conducir a amputaciones y aún, comprometer la vida del paciente. En una entrega anterior desarrollamos aspectos generales del pié en las personas con diabetes y en particular, el abordaje de las ulceras no infectadas. En esta entrega se profundiza sobre el abordaje y manejo de las infecciones del pie, particularmente de las lesiones ulceradas y la osteomielitis.

Clinical profile and management outcome of diabetic foot ulcers in a tertiary care hospital

To determine major risk factors and management outcome of diabetic foot ulcers in order to prevent amputation. Cross-sectional descriptive study. Study was conducted at the Department of Medicine, Civil Hospital Karachi, from January 2005 to December 2006. One-hundred and sixteen consecutive diabetic patients, with foot ulcers of Wagner's grade 1 to 4 were assessed at baseline for demographic information, detailed history, neuropathy, peripheral pulses and frequency of diabetic complication. Glycemic control was determined on the basis of HbA1c levels. Appropriate medical and surgical treatments were carried out and patients were followed-up until healing or for 6 months as end point of study. Outcome was recorded as healed, incomplete healing and amputated. A majority of subjects had type 2 diabetes [95.7%] with male predominance [66%]. The mean age was 54.29 +/- 7.71 years. Most of the patients were overweight, hyperglycemic and had diabetes > 10 years duration. Neuropathic ulcers were found in 91 [78.4%] patients, while rest of the 25 [22.6%] had neuroischemic ulcers. Wound cultures revealed polymicrobial organisms. Foot ulcers of 89 [77.7%] patients healed without amputation and 17 [14.7%] patients had minor or major amputations. Long-duration of diabetes, poor glycemic control and type of foot ulcers had effect on prognosis [p<0.05]. Effective glycemic control, optimal wound care, aggressive medical management and timely surgical intervention may decrease disabling morbidity with better outcome of diabetic foot ulcer

Effects of iloprost [a prostacyclin analogue] on the endothelial dysfunction and foot ulcers in diabetic patients with peripheral arterial disease

To asses the efficiency of iloprost [an analogue of prostacyclin] infusion on endothelial functions and amputation rate in diabetic foot ulcers with complicated macroangiopathy Sixty [36 men/ 24 women] type 2 diabetic patients [61.8 +/- 9.7 years, mean +/- SD] with diabetic foot ulcer and peripheral arterial occlusive disease, stage III or more by Wagner classification, and 15 [9 male/ 6 female] healthy controls [60.7 +/- 9.1 years, mean +/- SD] were enrolled in the study. Thirty patients [group I] had iloprost infusion [0.5-2 ng/kg/min for 6 h] for 10 consecutive days. Endothelial functions were determined by brachial arterial flow mediated dilation [FMD] method at stage 0 [basal], 10th and 30th days. Group II patients [n=30] were treated in the same manner as group I except iloprost treatment constituting a patient control group Group I patients showed a significant improvement in the endothelial functions at 10th day, and 30th day [p=0.002] in respect to group II. There were no differences between group I and group II regarding the hospitalization period and amputation rates. Iloprost was well tolerated. Three patients had adverse reactions such as maculo-papular skin eruptions, itching, hypotension and dyspnea due to iloprost infusion; one completed the treatment and 2 had to discontinue the iloprost infusion. Ten-day iloprost infusion therapy to patients with diabetic foot ulcers seems to be efficient in the improvement of endothelial function, but, despite our positive clinical observation, this improvement does not affect the outcome of the amputation rates at 30 days follow up period

Total contact cast for neuropathic diabetic foot ulcers

To determine the outcome of diabetic neuropathic foot ulcers treated with Total Contact Cast [TCC] in terms of percentage of ulcers healed and time to heal. Department of Orthopaedic Surgery, Abbasi Shaheed Hospital, Karachi Medical and Dental College, from April 2005 to March 2007. The study included diabetic patients with non-ischemic neuropathic foot ulcers of upto grade 2 of Wagner's classification. Ulcers were debrided off necrotic tissues and Total Contact Cast [TCC] was applied. TCC was renewed every 2 weeks till healing. Cases were labeled as cast failure when there was no reduction in wound size in 4 consecutive weeks or worsening to a higher grade. Main outcome measures were the percentage of ulcers healed and time to heal in the cast. Thirty four [87.17%] patients were males and 5[12.82%] were females. The mean age was 62 +/- 13.05 years. All patients had NIDDM. Out of the 52 ulcers, 41[78.84%] healed with TCC in an average 2 casts duration [mean 32 days]. There were 11[21.15%] cast failure. Majority [63.63%] of cast failure ulcers were located on pressure bearing area of heel. Most [90%] of the ulcers on forefoot and midsole region healed with TCC [p<0.001]. Longer ulcer duration [mean 57.45 +/- 29.64 days] significantly reduced ulcer healing [p<0.001]. Total contact cast was an effective treatment modality for neuropathic diabetic foot ulcers of Wagner's grade 2, located on forefoot and midsole region

Pé diabético: tratamento das úlceras plantares com gesso de contato total e análise dos fatores que interferem no tempo de cicatrização / Treatment of diabetic foot plantar ulcers with total contact casting and analysis of factors that interfere with healing time

O objetivo do presente trabalho é analisar os fatores que interferem no tempo de cicatrização das úlceras plantares tratadas com gesso de contato total (GCT), em pés neuropáticos de pacientes diabéticos. São estudados 32 pacientes diabéticos com úlceras graus I e II da classificação de Wagner, acompanhados por um período de dois anos. Os pacientes são diabéticos em média há 14,4 anos; 12,5 por cento são insulino-dependentes e 87,5 por cento diabéticos não insulino-dependentes. São tratados pelo método do GCT em sua forma fechada ou aberta, obtendo-se a cicatrização de todas as úlceras em um prazo médio de 46,3 dias. As variáveis analisadas são agrupadas em categóricas (sexo, lateralidade, dependência de in- sulina, localização da úlcera no pé, uso do gesso em sua for- ma fechada ou aberta e grau da úlcera) e quantitativas (idade, tempo de doença, tempo de duração e tamanho da úlcera). Os autores concluem que a única variável que interfere com o tempo de cicatrização é o tamanho da úlcera e que por meio de um modelo matemático ajustado pode-se estimar o tempo de cicatrização da mesma a partir do seu tamanho

Ulceras venosas de miembros inferiores: fisiopatogenia, Manifestaciones clinicas y tratamiento / Venous leg ulcers

Muchos médicos encuentran que las úlceras venosas es una patología de difícil manejo. Esta enfermedad no es rara y su tratamiento varía según las características de la úlcera y del paciente. Presentamos una revisión de la literatura en la que se incluyeron aspectos de su fisiopatogenia, semiología, diagnóstico y tratamiento

The vacuum assisted closure of complex wounds: report of 3 cases

Treatment of wounds using conventional methods is frequently limited by inadequate local wound conditions, or by a poor systemic clinical situation. Vacuum system may promote faster granulation tissue formation, remove excessive exudate, increase blood flow in the wound, and attract the borders of the wound to the center, reducing its dimension. We present 3 cases of patients with difficult wounds, due to bad local conditions, or poor clinical situation, in whom we used a vacuum system to prepare the wound for the surgical closure. One patient had a pressure ulcer, another had a diabetic foot ulcer, and the third one had an open foot stump. In the 3 cases a significant improvement of the wound conditions was achieved after 7 to 8 days, allowing successful surgical treatment with flap or skin grafts